Department of Pulmonary Diseases, Baskent University School of Medicine, Ankara, Turkey.
Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):E87-94. doi: 10.1177/1076029610385224. Epub 2010 Nov 15.
Venous thromboembolism (VTE) is a universal health hazard. Inherited and acquired risk factors increase the risk of VTE. We evaluated the relationship between factor V (G1691A, A1090G, and A1299G), prothrombin (PT G20210A), methylenetetrahydrofolate reductase (MTHFR C677T) mutations, plasminogen activator inhibitor 1 (PAI-1 -675) polymorphism, and VTE in Turkish population. In all, 80 patients with VTE and 104 controls were included. Heterozygous factor V Leiden (FVL) mutation was significantly higher among patients (P = .04) with allele frequency of 6.3% (P = .01). Heterozygous PT G20210A mutation was also significantly higher among patients (P = .001) with allele frequency of 6.9% (P = .003). MTHFR 677TT genotype was significantly higher in patients (P = .009) with allele frequency of 23.8% (P = .005). No significant difference was found in FV A1090G and FV A1299G mutation rate as well as PAI-1 genotypes and their allele frequencies (P > .05). Thus, frequencies of FV G1691A, PT G20210A, and MTHFR C677T mutations are higher in patients with VTE. FV A1090G, FV A1299G mutations, and PAI-1 gene polymorphisms may not be a risk factor for VTE in Turkish population.
静脉血栓栓塞症(VTE)是一种普遍存在的健康危害。遗传和获得性危险因素会增加 VTE 的风险。我们评估了因子 V(G1691A、A1090G 和 A1299G)、凝血酶原(PT G20210A)、亚甲基四氢叶酸还原酶(MTHFR C677T)突变、纤溶酶原激活物抑制剂 1(PAI-1 -675)多态性与土耳其人群 VTE 之间的关系。共纳入 80 例 VTE 患者和 104 例对照者。杂合子因子 V 莱顿(FVL)突变在患者中明显更高(P =.04),等位基因频率为 6.3%(P =.01)。杂合子 PT G20210A 突变在患者中也明显更高(P =.001),等位基因频率为 6.9%(P =.003)。MTHFR 677TT 基因型在患者中明显更高(P =.009),等位基因频率为 23.8%(P =.005)。FV A1090G 和 FV A1299G 突变率以及 PAI-1 基因型及其等位基因频率无显著差异(P >.05)。因此,VTE 患者中 FV G1691A、PT G20210A 和 MTHFR C677T 突变的频率较高。FV A1090G、FV A1299G 突变和 PAI-1 基因多态性可能不是土耳其人群 VTE 的危险因素。